Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Summit Therapeutics Announces Exercise of Underwriters' Over-Allotment Option | ||||||||||||||||
By: Nasdaq / GlobeNewswire - 15 Sep 2017 | Back to overview list |
|||||||||||||||
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
Summit Therapeutics plc
SUMMIT THERAPEUTICS ANNOUNCES EXERCISE OF UNDERWRITERS' OVER-ALLOTMENT OPTION Oxford, UK, 15 September 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, today announces that the underwriters of its underwritten public offering have exercised in full their over-allotment option to purchase an additional 218,850 American Depositary Shares ("ADSs") at the public offering price of $12.00 per ADS, less underwriting discounts and commissions. After the over-allotment exercise, the total number of ADSs to be sold by Summit in this public offering will increase to 1,677,850. The ADSs trade on the NASDAQ Global Market. Each ADS represents five ordinary shares of Summit. Application is being made for 8,389,250 new ordinary shares in the Company, represented by the 1,677,850 ADSs to be issued at the closing of the offering, to be admitted to trading on the AIM market. It is expected that admission and dealing in these new ordinary shares will occur on or around 19 September 2017. The new ordinary shares will rank pari passu with the Company's existing ordinary shares. Canaccord Genuity Inc. and JMP Securities LLC are acting as joint lead book-running managers for the offering. Needham & Company, LLC is acting as lead manager and H.C. Wainwright & Co., LLC is acting as co-manager. The securities are being issued and sold pursuant to an effective shelf registration statement (including a base prospectus) that was previously filed with the Securities and Exchange Commission (the "SEC"). The final prospectus supplement relating to the offering was filed with the SEC on September 14, 2017 and is available on the SEC's website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained by contacting Canaccord Genuity Inc., Attention: Syndicate Department, 99 High Street, 12th Floor, Boston, Massachusetts 02110, telephone: +1 (617) 371-3900 or JMP Securities LLC, Prospectus Department, 600 Montgomery Street, 10th Floor, San Francisco, California 94111, telephone: +1 (415) 835- 8985. This press release is being issued pursuant to and in accordance with Rule 135e under the United States Securities Act of 1933, as amended (the "Securities Act"). This press release does not constitute a prospectus and does not constitute or form part of any offer or invitation to sell or issue, or the solicitation of an offer to purchase or acquire, any of the ordinary shares or ADSs or any other securities in the United States of America or in any other jurisdiction. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the Securities Act. Any public offering of securities to be made in the United States will be made by means of a prospectus. Such prospectus will contain or incorporate by reference detailed information about the issuer and its management and financial statements. In particular, and without limitation, no offer of securities to the public (as that term is understood in the EU Prospectus Directive) is being made in the United Kingdom or in any other country in the European Economic Area which has implemented the EU Prospectus Directive. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR).
About Summit Therapeutics
For more information, please contact:
Forward Looking Statements
-END-
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Summit Therapeutics plc via GlobeNewswire
HUG#2134528
|
||||||||||||||||
|
||||||||||||||||
Copyright 2017 Nasdaq / GlobeNewswire | Back to overview list |